HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • 2023 Salary Survey
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Webinars
    • Conferences
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists

Peterson Center on Healthcare Launches Institute to Evaluate Digital Health Technologies

The Peterson Center on Healthcare has launched the Peterson Health Technology Institute (PHTI). The PHTI is a nonprofit organization dedicated to evaluating and assessing innovative healthcare technologies. With a $50 million commitment from the Peterson Center, PHTI aims to analyze the clinical […]

more info 07/19/2023View Related Articles
Bookmark and Share

Novo Nordisk Grapples with Supply Shortage Amid Surging Demand for Weight-Loss Drugs

Novo Nordisk is facing a supply shortage for its weight-loss drugs, Wegovy and Saxenda, due to surging demand… Here’s What You Need to Know: After initial Wegovy shortages, customers turned to Saxenda for a replacement, leading to its limited availability through the end of 2023 and possibly […]

more info 07/19/2023View Related Articles
Bookmark and Share

ITIF Report: Global Drug Price Controls Restrict Pharmaceutical Research and Development

The Information Technology and Innovation Foundation (ITIF) study reports that drug price controls in non-US Organization for Economic Cooperation and Development (OECD) nations inhibit biopharmaceutical R&D by over $56 billion annually, foregoing the creation of around 25 new drugs yearly. If […]

more info 07/18/2023View Related Articles
Bookmark and Share

Economists Suggest That Universal Coverage Is Already Possible for the US: What Obstacles Still Stand in the Way?

The current state of health insurance in the U.S. needs to be revised, even for insured Americans who face the risk of massive medical bills for their covered care. The coverage is unstable, and the Affordable Care Act did relatively little to reduce the risk of insurance loss among those insured. […]

more info 07/18/2023View Related Articles
Bookmark and Share

BridgeBio’s Experimental Results Boosts Company Shares by 65%

BridgeBio Pharma Inc's experimental drug, acoramidis, for rare heart disease, has shown significant improvement in a late-stage study, boosting its market shares by 65%. Acoramidis functions to prevent heart failure by addressing anomalous protein deposits in the heart. It is expected to compete […]

more info 07/17/2023View Related Articles
Bookmark and Share

FDA Approves AstraZeneca’s Beyfortus

The Food and Drug Administration has approved an AstraZeneca-developed monoclonal antibody, Beyfortus, in an effort to protect infants and young children from severe illness caused by RSV, the number 1 cause of infant hospitalizations in the U.S. Beyfortus is expected to be recommended by the […]

more info 07/17/2023View Related Articles
Bookmark and Share

J&J Subsidiary Sues Doctors Over Talc-Cancer Research

Johnson & Johnson's subsidiary LTL Management has filed lawsuits against four doctors who have published studies suggesting links between J&J's talc-based care products, including Baby Powder, and cancer. The company insists these studies are inaccurate and demands a retraction or […]

more info 07/14/2023View Related Articles
Bookmark and Share

Revolution in Women’s Health: First Over-The-Counter Contraceptive Coming to U.S. Shelves in 2024!

Perrigo's oral contraceptive, Opill, is now the first over-the-counter birth control pill in the United States. Opill has been around since the early 1970s and received approval from the FDA in a unanimous 17 to 0 vote back in May. Now, Opill will be available nonprescription to patients of all […]

more info 07/14/2023View Related Articles
Bookmark and Share

Sequoia Project and AHIMA Launch Health Data Usability Project

The Sequoia Project and the American Health Information Management Association (AHIMA) have partnered on the initiative "Data Usability Taking Root." They designed this project to enhance the quality and actionability of the health information that end users receive within their workflows. Eleven […]

more info 07/13/2023View Related Articles
Bookmark and Share

BioGeneration Ventures Finalizes $167M Fund for Biotech Startups in Europe

What You Need To Know: Dutch venture capital firm BioGeneration Ventures (BGV) has secured €150 million ($167 million) for its fifth fund. The firm bases itself in Naarden, Netherlands, focusing on European drug developers. However, 78% of the new investors, forming most of the new investor […]

more info 07/13/2023View Related Articles
Bookmark and Share

Insights into the Global Real World Evidence Solutions Market 2023-2030

10 Things You Need to Know:  The projection shows the market size growing from $16.3 billion in 2023 to $36.24 billion in 2030, with a CAGR of 12.3%. IQVIA Inc., UnitedHealth Group, IBM, and Cognizant are currently the major players to pay attention to in the market. Advanced analytics […]

more info 07/12/2023View Related Articles
Bookmark and Share

Unmasking Healthcare Costs: Beyond Transparency

What You Need to Know:  Policymakers have shifted focus towards price transparency in healthcare to combat escalating costs; however, merely comprehending the cost increase will not tackle the entire issue. Healthcare providers and health plans must post their prices online under federal […]

more info 07/12/2023View Related Articles
Bookmark and Share

Is AI the Future of Pharma?

Here's What People Are Saying...  ChatGPT is revolutionizing the pharmaceutical industry. Artificial intelligence and machine learning are expediting medication development, tailoring drug distribution, and improving the process of drug commercialization. Big pharma companies like Pfizer, Merck […]

more info 07/11/2023View Related Articles
Bookmark and Share

Price Break: Cigna Welcomes Trio of Discounted Biosimilars to Preferred Drug Roster

What You Need to Know:  Cigna Group's unit, Express Scripts, is adding three biosimilar versions of AbbVie's arthritis treatment Humira to its preferred drugs list. Reuters explains that “The biosimilars include Hyrimoz and an unbranded version of Humira from Swiss drugmaker Novartis' […]

more info 07/11/2023View Related Articles
Bookmark and Share

Will the Medicare Price Negotiation Revamp Sufficiently Appease Pharma Companies?

The Centers for Medicare & Medicaid Services (CMS) amendments to its drug pricing negotiation program will unlikely deter past, current, and future industry legal challenges. The CMS recently released a highly-anticipated strategy for setting and negotiating prescription drug prices after going […]

more info 07/10/2023View Related Articles
Bookmark and Share

Thermo Fisher to Acquire Data Firm CorEvitas for $912.5M

What You Need to Know:  For $912.5 million, Thermo Fisher Scientific is set to acquire CorEvitas, a real-world data intelligence company. CorEvitas has developed a platform that collects structured clinical patient data from over 400 sites and more than 100,000 patients. According to Fierce, […]

more info 07/10/2023View Related Articles
Bookmark and Share

Accelerating the Rise of Value-Based Care

Enacting value-based care payment models has been a priority of payer and provider organizations in recent years, but the implementation has been uneven, with care centers serving underprivileged or vulnerable populations being left in the lurch. Helping close the gap is pivotal to reaching the US […]

more info 07/07/2023View Related Articles
Bookmark and Share

Looking Back at the Orphan Drugs Act

In 1983, the US Congress passed the Orphan Drug Act (ODA) that offers financial incentives for developing drugs for rare diseases that have limited, if any, approved therapeutics. A new study published in the Orphanet Journal of Rare Diseases explores the impact that the ODA has had on the field of […]

more info 07/07/2023View Related Articles
Bookmark and Share

Examining the Five Biggest Players in Medicaid Managed Care

With over 70% of Medicaid beneficiaries being enrolled in plans from managed care organizations (MCOs), managed care has become a major player in the American health insurance industry. A new article by the Kaiser Family Foundation (KFF) takes a look at five of the largest MCOs and how they are […]

more info 07/07/2023View Related Articles
Bookmark and Share

ICER Faces Backlash for Proposed Changes to Value-Assessment Framework

The Institute for Clinical and Economic Review has received industry backlash over changes to its value-assessment process it proposed in June. The changes, if implemented, would lower the threshold ranges for cost-effectiveness down to $50,000 to $100,000 a year, a net drop of $50,000 at each end […]

more info 07/07/2023View Related Articles
Bookmark and Share

Biden Administration Rolls Back Limit on Short-Term Health Plans

The Biden administration and the US Department of Health and Human Services (HHS) have put forward a proposed rule that would set the limit for short-term health insurance to 4 months, reversing a Trump-era rule that gave them durations up to one year with the chance of renewal. Democrats derided […]

more info 07/07/2023View Related Articles
Bookmark and Share

Study Finds Many New Drug Indications Don’t Add Value

A newly published study in the BMJ finds that almost 60% of drugs receiving new indications from the US Food and Drug Administration (FDA) do not add high therapeutic value to patients. As a result, the researchers argue that patients and providers should be aware and that prices should be set […]

more info 07/06/2023View Related Articles
Bookmark and Share

Alzheimer’s Drug Leqembi Gets Full FDA Approval and Medicare Coverage

Eisai and Biogen’s Alzheimer’s treatment Leqembi (lecanemab) has received full approval by the US Food and Drug Administration (FDA). This marks the first full approval for an Alzheimer’s disease treatment in decades and clears the path to Medicare reimbursement, which previously required providers […]

more info 07/06/2023View Related Articles
Bookmark and Share

Expert Panel Agrees Recent Regulation has Advanced Real-World Data Applications

A panel of regulatory experts discussed how regulatory initiatives have advanced the use of real-world data (RWD) at this June’s Drug Information Association’s global meeting. The panelists, who came from the US Food and Drug Administration (FDA), Health Canada (HC), European Medicines Agency (EMA), […]

more info 07/06/2023View Related Articles
Bookmark and Share

Using Real-World Evidence to Assess Hepatotoxicity of Biologics

A real-world evidence (RWE) study published in Nature Scientific Reports assessed the hepatotoxicity of several major biologics, such as adalimumab, trastuzumab, IF-Beta 1a, and insulin glargine. The study, which used real-world data (RWD) from over 2 million patients, found that many of these key […]

more info 07/06/2023View Related Articles
Bookmark and Share

Major Hospitals Join Legal Battle Over High Generic Drug Prices

The Mayo Clinic, Mount Sinai, and around 150 other hospitals have joined other care centers in suing major drug manufacturers over inflated prices for generic medications. The lawsuit alleges that drugmakers like Pfizer, Sandoz, and Teva have illegally collaborated for over a decade to keep generic […]

more info 07/06/2023View Related Articles
Bookmark and Share

Clinical Trial Diversity on the Decline

According to a recent IQVIA report, clinical trial diversity is on the downswing despite recent efforts to the contrary. The research specifically identified significant under-representation for Black and Hispanic patients. Industry action is needed, according to IQVIA, as clinical trial […]

more info 07/05/2023View Related Articles
Bookmark and Share

Samsung and Pfizer Expand Collaboration to Accelerate Biosimilar Production

Samsung Biologics and Pfizer have announced they are expanding their current collaboration to ramp up production of biosimilars, bringing the agreement to a value of $897 million. The announcement comes as Pfizer and another branch of Samsung both prepare for US launches of their Humira […]

more info 07/05/2023View Related Articles
Bookmark and Share

UK Public Okay with NHS Data Storage with Some Reservations

The UK’s NHS generates massive amounts of real-world data (RWD) every day, but recently data security has become a concern. However, a recent survey found that 59% of participants feeling comfortable with the agency storing their data, although most (89%) felt it was important that the data was […]

more info 07/05/2023View Related Articles
Bookmark and Share

US Senator Bernie Sanders Looks to Cap Prices on Publicly Funded Drugs

US Senator Bernie Sanders (I – VT) is looking to include price caps on drugs developed with federal funding into a reauthorization of the 2006 Pandemic and All-Hazards Preparedness Act. The proposal would place a ceiling price that matches the lowest price for a given drug in France, Germany, Japan, […]

more info 07/05/2023View Related Articles
Bookmark and Share

  • Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 244
  • Next Page

 

Advertise With Us!View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Webinar of the Week
Conference of the Week
Link of the Week

HealthEconomics.Com Jobs Portal

    No feed items found.

 
Syndicated Reports

Biotech R&D: a target-rich environment

Global Gene Therapy Report 2022-2031

ePrescribing Market – This is How Key Players are Dominating Global Industry

Health Economics and Outcomes Research (HEOR) Services Market to 2028

 
White Papers

Real World Evidence Solutions Global Market Report 2022

AI for Pharma and Biotech Market Pricing Strategy, Industry Latest News, Top Company Analysis, Research Report Analysis and Share by Forecast 2026

Whitepaper – Engaging the End Prescriber: A Practical Guide to Working With Physicians

Adaptive Trial Designs in Early Oncology: Minimizing Risk & Accelerating Timelines

HealthEconomics.Com

HealthEconomics.Com

  • Become a Better Writer!
  • News
  • Conferences
  • Jobs
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • 2023 Salary Survey
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Webinars
    • Conferences
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists